At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
CPRX Catalyst Pharmaceuticals
Market Closed 12-20 16:00:00 EST
21.27
-0.19
-0.89%
盘后21.68
+0.41+1.93%
19:48 EST
High21.41
Low21.01
Vol1.75M
Open21.27
D1 Closing21.46
Amplitude1.86%
Mkt Cap2.54B
Tradable Cap2.25B
Total Shares119.27M
T/O37.25M
T/O Rate1.66%
Tradable Shares105.79M
P/B--
ROE--
EPS0.00
52wk High--
52wk Low--
P/E--
Dividend--
Div.Yield--
ROA--
Bank of America Securities Sticks to Its Buy Rating for Catalyst Pharma (CPRX)
Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients. The company develops Firdapse for the treatment of MuSK antibody positive myasthenia gravis and spinal muscular atrophy type. It has license agreements with BioMarin Pharmaceutical Inc.; and collaboration and license agreement with Endo Ventures Limited for the development and commercialization of generic Sabril tablets. The company was founded in 2002 and is based in Coral Gables, Florida.